Recent Insights into the Role of the Insulin-Like Growth Factor Axis in Preeclampsia

Kappou, Dimitra; Vrachnis, Nikos; Sifakis, Stavros

doi:10.5772/37881

Cited by 3 publications

(3 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…31 Penurunan kadar protein IGF-1R juga diikuti oleh gangguan aktivasi molekul persinyalan intrasel sehingga masalah IUGR dapat terjadi. 32 Masih terdapat kontroversi terkait peran IGF-1 terhadap pertumbuhan janin, karena IGF-1 maternal tidak melintasi plasenta. 17 Mekanisme bagaimana IGF-1 mempengaruhi pertumbuhan janin kemungkinan besar melalui stimulasi fungsi plasenta dan meningkatkan suplai nutrisi bagi janin.…”

Section: Pendahuluanunclassified

Hubungan kadar <em>insulin-like growth factor 1</em> serum maternal dengan berat badan dan panjang badan bayi baru lahir pada ibu hamil KEK

Nasution¹,

Lipoeto²,

Yulizawati³

2019

Maj Kedokt Andalas

View full text Add to dashboard Cite

Tujuan: Untuk mengetahui hubungan kadar IGF-1 dengan berat badan dan panjang badan bayi baru lahir pada ibu hamil dengan kekurangan energi kronik. Metode: Penelitian ini dilakukan dii Puskesmas Belimbing dan Puskesmas Lubuk Buaya Kota Padang pada bulan Oktober sampai Desember 2018. Penelitian ini menggunakan metode analitik korelatif dengan desain potong lintang. Analisis data menggunakan uji korelasi Spearman dengan nilai p<0,05 dianggap bermakna secara statistik. Sampel penelitian sebanyak 40 orang ibu hamil dengan kekurangan energi kronik. Hasil: Hasil penelitian menunjukkan terdapat hubungan yang bermakna antara kadar IGF-1 serum maternal dengan berat badan lahir bayi (p=0,001; r=0,493), namun tidak terdapat hubungan yang bermakna antara kadar IGF-1 serum maternal dengan panjang badan lahir bayi (p=0,105; r=0,260). Simpulan: Terdapat hubungan kadar IGF-1 serum maternal dengan berat badan lahir bayi.

show abstract

Section: Pendahuluanunclassified

Hubungan kadar <em>insulin-like growth factor 1</em> serum maternal dengan berat badan dan panjang badan bayi baru lahir pada ibu hamil KEK

Nasution¹,

Lipoeto²,

Yulizawati³

2019

Maj Kedokt Andalas

View full text Add to dashboard Cite

show abstract

“…Abnormal placentation with inadequate cytotrophoblastic invasion occurs in preeclamptic pregnancies with resultant ischemia, and is associated with vascular abnormalities, immune dysfunction, oxidative stress, and imbalances of growth and angiogenic factors [5]. Long implicated in both the pathogenesis and systemic sequelae of preeclampsia are various derangements involving the insulin-like growth factor-1 (IGF-1) axis [19]. In particular, many reports have described low IGF-1 blood levels as well as decreased placental expression of IGF-1 in women with preeclampsia, and this has been hypothesized to play a role in the future risk of breast and other cancers [20][21][22][23][24][25].…”

Section: Introductionmentioning

confidence: 99%

A common IGF1R gene variant predicts later life breast cancer risk in women with preeclampsia

Powell

Fuller

Gunderson

et al. 2022

Preprint

View full text Add to dashboard Cite

PurposePreeclampsia has been inconsistently associated with altered later-life risk of cancer. This study utilizes the Nurses’ Health Study 2 to determine if the future risk of breast and non-breast cancers in women who experience preeclampsia is modified by carrying a protective variant of rs2016347, a functional insulin-like growth factor receptor-1 (IGF1R) single nucleotide polymorphism. MethodsThis retrospective cohort study enrolled participants in 1989 and followed them through 2015, with a study population of 86,751 after exclusions. Cox proportional hazards models both with and without the impact of rs2016347 genotype were used to assess the risk of all breast cancer, hormone receptor-positive (HR+) breast cancer, and non-breast cancers. ResultsWomen with preeclampsia had no change in risk of all breast, HR+ breast, or non-breast cancers when not considering genotype. However, women carrying at least one T allele of rs2016347 had a lower risk of HR+ breast cancer, HR = 0.67, 95% CI: 0.47-0.97, P = 0.04, with interaction term P = 0.06. For non-breast cancers as a group, women carrying a T allele had an HR = 0.76, 95% CI: 0.53-1.08, P = 0.12, with interaction term P = 0.26. ConclusionsThis retrospective cohort study found that women with preeclampsia who carry a T allele of IGF1R rs2016347 had a reduced future risk of developing HR+ breast cancer, and a reduced but not statistically significant decreased risk of non-breast cancers suggesting a possible role for the IGF-1 axis in the development of cancer in these women.

show abstract

“…The systemwide sequelae of preeclampsia have long been noted and debated; and while preeclampsia is still primarily considered a placental disorder its exact pathogenesis remains unclear. Postulated systemic impacts include vascular ischemia, immune dysfunction, oxidative stress, and dysregulated angiogenesis, along with derangements of the insulin-like growth factor-1 (IGF-1) axis [ 5 , 19 ]. With regard to the latter, several reports have described low IGF-1 blood levels as well as decreased placental expression of IGF-1 in women with preeclampsia, and this has been hypothesized to play a role in the future risk of breast and other cancers [ 20 – 25 ].…”

Section: Introductionmentioning

confidence: 99%

A common IGF1R gene variant predicts later life breast cancer risk in women with preeclampsia

Powell

Fuller

Gunderson

et al. 2022

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose Preeclampsia has been inconsistently associated with altered later life risk of cancer. This study utilizes the Nurses’ Health Study 2 (NHS2) to determine if the future risk of breast and non-breast cancers in women who experience preeclampsia is modified by carrying a protective variant of rs2016347, a functional insulin-like growth factor receptor-1 (IGF1R) single nucleotide polymorphism. Methods This retrospective cohort study completed within the NHS2 evaluated participants enrolled in 1989 and followed them through 2015, with a study population of 86,751 after exclusions. Cox proportional hazards models both with and without the impact of rs2016347 genotype were used to assess the risk of invasive breast cancer, hormone receptor-positive (HR+) breast cancer, and non-breast cancers. Results Women with preeclampsia had no change in risk of all breast, HR+ breast, or non-breast cancers when not considering genotype. However, women carrying at least one T allele of rs2016347 had a lower risk of HR+ breast cancer, HR 0.67, 95% CI: 0.47–0.97, P = 0.04, with interaction term P = 0.06. For non-breast cancers as a group, women carrying a T allele had an HR 0.76, 95% CI: 0.53–1.08, P = 0.12, with interaction term P = 0.26. Conclusions This retrospective cohort study found that women with preeclampsia who carry a T allele of IGF1R rs2016347 had a reduced future risk of developing HR+ breast cancer, and a reduced but not statistically significant decreased risk of non-breast cancers suggesting a possible role for the IGF-1 axis in the development of cancer in these women.

show abstract

Recent Insights into the Role of the Insulin-Like Growth Factor Axis in Preeclampsia

Cited by 3 publications

References 82 publications

Hubungan kadar <em>insulin-like growth factor 1</em> serum maternal dengan berat badan dan panjang badan bayi baru lahir pada ibu hamil KEK

Hubungan kadar <em>insulin-like growth factor 1</em> serum maternal dengan berat badan dan panjang badan bayi baru lahir pada ibu hamil KEK

A common IGF1R gene variant predicts later life breast cancer risk in women with preeclampsia

A common IGF1R gene variant predicts later life breast cancer risk in women with preeclampsia

Contact Info

Product

Resources

About